In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Revance Therapeutics (RVNC – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $3.64.
According to TipRanks, Prasad is a 2-star analyst with an average return of 0.0% and a 39.57% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Zoetis, and Alvotech.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Revance Therapeutics with a $15.80 average price target.
RVNC market cap is currently $379.3M and has a P/E ratio of -0.96.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RVNC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics (RVNC) Company Description:
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
